Cassava Sciences Inc. SAVA stock plunged Monday after the company released topline data from the Phase 3 ReThink-ALZ study of simufilam in mild-to-moderate Alzheimer’s disease.The trial did not meet the pre-specified co-primary, secondary, and exploratory biomarker endpoints.In July, CEO Rick Barry wrote a letter to shareholders and employees, saying that the company is in the final stages of testing simufilam and has significant financial and emotional stakes.The co-primary endpoints were the change in cog ...